Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START antiplatelet registry.

[1]  N. Hamburg.  Clinical Outcomes of Women With PAD: A New Perspective. , 2020, Journal of the American College of Cardiology.

[2]  E. Antonucci,et al.  Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry , 2019, Angiology.

[3]  C. Reid,et al.  Outcomes in patients with peripheral vascular disease following percutaneous coronary intervention , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  K. Rahimi,et al.  Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. , 2019, The Lancet. Global health.

[5]  A. Gori,et al.  Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry , 2019, PloS one.

[6]  M. Zubaid,et al.  Association between Peripheral Artery Disease and Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome: Findings from the Gulf COAST Registry , 2019, Medical Principles and Practice.

[7]  E. Antonucci,et al.  Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry , 2018, Angiology.

[8]  A. Peters,et al.  Peripheral arterial disease is associated with higher mortality in patients with incident acute myocardial infarction. , 2018, European journal of internal medicine.

[9]  S. Johansson,et al.  Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom , 2018, Thrombosis and Haemostasis.

[10]  P. Gresele.  Coronary and peripheral artery atherosclerosis: what choice for antiplatelet therapy , 2018, Journal of cardiovascular medicine.

[11]  L. Brewster,et al.  Statins have a dose-dependent effect on amputation and survival in peripheral artery disease patients , 2018 .

[12]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[13]  J. Massaro,et al.  Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. , 2017, JACC. Cardiovascular interventions.

[14]  Deepak L. Bhatt,et al.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.

[15]  A. Peters,et al.  Presenting symptoms, pre-hospital delay time and 28-day case fatality in patients with peripheral arterial disease and acute myocardial infarction from the MONICA/KORA Myocardial Infarction Registry , 2017, European journal of preventive cardiology.

[16]  Marc P. Bonaca,et al.  Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction , 2016, Circulation.

[17]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[18]  B. Katzen,et al.  Bleeding Risk Profile in Patients With Symptomatic Peripheral Artery Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[19]  I. Bairati,et al.  Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease , 2016, PloS one.

[20]  K. Mahaffey,et al.  Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial , 2015, European journal of preventive cardiology.

[21]  K. Cross,et al.  Peripheral artery disease: a marked lack of awareness in Ireland. , 2015, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[22]  Deepak L. Bhatt,et al.  Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study , 2015, European journal of preventive cardiology.

[23]  J. Li,et al.  Incidence and related factors of upper gastrointestinal bleeding in a Chinese population of peripheral arterial disease during a six-year follow-up. , 2014, International angiology : a journal of the International Union of Angiology.

[24]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[25]  S. Solomon,et al.  Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. , 2013, International journal of cardiology.

[26]  P. Gresele.  Antiplatelet agents in clinical practice and their haemorrhagic risk. , 2013, Blood transfusion = Trasfusione del sangue.

[27]  M. Kibbe,et al.  Peripheral arterial disease in women. , 2013, Journal of vascular surgery.

[28]  V. Aboyans,et al.  Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. , 2012, Circulation.

[29]  Manesh R. Patel,et al.  Missed Opportunities: Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains , 2012, Circulation.

[30]  P. Gresele,et al.  The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new? , 2008, European heart journal.

[31]  P. Gresele,et al.  Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease. , 2008, Family practice.

[32]  M. Criqui,et al.  Gaps in Public Knowledge of Peripheral Arterial Disease: The First National PAD Public Awareness Survey , 2007, Circulation.

[33]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[34]  W. Howard.  Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. , 2007, Journal of vascular surgery.

[35]  Deepak L. Bhatt,et al.  The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. , 2006, Journal of the American College of Cardiology.

[36]  F. Fowkes,et al.  Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. , 2006, European heart journal.

[37]  Rodney A. White,et al.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.

[38]  B. Gersh,et al.  Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. , 2004, Mayo Clinic proceedings.

[39]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[40]  B. Lewis,et al.  Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 stu , 2003, American heart journal.

[41]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.